Table 1 Characteristics of medical error reports included in the study
Sample characteristics (n = 199) | n (%) |
|---|---|
Number of reported medical error/setting | |
Hospitals | 109 (54.8%) |
SFDA | 90 (45.2%) |
Age in years: median (IQ range) | 63.5 (48.0–76.0) |
Gender: n = 198 | |
Male | 99 (50.0%) |
Female | 99 (50.0%) |
Weight in kg: median (IQ range) | 75 (63.0–89.0) |
Height in cm: median (IQ range) | 161 (154.0–169.0) |
Comorbidities | 188 (94.5%) |
DOAC type | |
Apixaban | 134 (67.3%) |
Dabigatran | 28 (14.1%) |
Rivaroxaban | 37 (18.6%) |
Indications for DOAC | |
Atrial fibrillation (AF) | 113 (56.8%) |
Deep vein thrombosis (DVT) | 55 (27.6%) |
Pulmonary embolism (PE) | 20 (10.1%) |
Cerebral venous thrombosis (CVT) | 2 (1.0%) |
Others | 9 (4.5%) |
DOAC dose at the incidence day: (only for the hospitals dataset) | |
Not reported | 2 (1.8%) |
Under-dose | 40 (36.7%) |
Optimum dose | 47 (43.2%) |
Over-dose | 6 (5.5%) |
+ + Over-dose | 14 (12.8%) |
Medication error type | |
Prescribing | 162 (81.4%) |
Dispensing | 21 (10.6%) |
Administration | 9 (4.5%) |
Monitoring | 4 (2.0%) |
Storage | 3 (1.5%) |
Medication error subtype | |
Medication-duplicate therapeutic category | 33 (16.6%) |
Wrong patient | 25 (12.6%) |
Incorrect dose | 44 (22.1%) |
Incorrect frequency | 29 (14.6%) |
Incorrect quantity | 30 (15.1%) |
Incorrect duration | 11 (5.5%) |
Incorrect medication | 9 (4.5%) |
Delay preparation | 4 (2.0%) |
Improper/lack of documentation | 4 (2.0%) |
Side effects | 2 (1.0%) |
Contraindicated drug/drug interactions | 8 (4.0%) |
Duration of DOAC when incidence happened (days): median (IQ range) | 90 (30–180) |
e-GFR at the day of incidence (only for the hospitals) | |
Mean ± SD | 78.61 ± 33.21 |
Range | (0–173) |